Coherus BioSciences, Inc. and Baxter International Inc. have amended certain financial terms of their collaboration from August 2013 for the development and commercialization of CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets.   Under the amended agreement, certain existing milestones and funding obligations have been revised, and the collaboration has been expanded to include select pre-commercialization activities. In total, the revis...